Telomere dysfunction is a major determinant of aging, degenerative diseases and cancer. In cancer, the telomeres and telomerase have been shown to play critical roles in the initiation and progression of malignancy. Telomere dysfunction, coupled with deactivated p53 checkpoints, enables genome instability and the development and progression of cancer, including metastasis. Significant effort in the current grant has been elucidating the wiring of the p53-dependent telomere checkpoint response and how p53 downstream targets promote degenerative conditions and enable malignant progression. Building on our ongoing work, this renewal will address two important areas of study. First area focuses on two critical targets of the p53 pathway. Work from current funding period from my laboratory has identified a profound deficiency in mitochondria biogenesis and function in telomere dysfunctional mice which results from p53-directed repression of PGC11/2 transcriptional coactivators, the master regulators of mitochondrial biogenesis and p53-directed activation of Quaking (QK), a RNA binding protein which we show is a potent tumor suppressor and regulator of microRNA-directed control of the key mitochondrial regulator, PPARa. These observations have led to the hypothesis that mitochondriopathy and associated energy loss is the primary cause of age related maladies in telomere dysfunctional mice and may dictate certain metabolic responses in cancer cells. The objectives of this competitive renewal will be to genetically assess the telomere-mitochondria link in aging and cancer. The specific efforts focus on (i) the use of an inducible telomerase model (TERT-ER) to assess the regenerative impact on mitochondrial biology and degenerative phenotypes in stem cells and diverse post-mitotic organ systems in aged telomere dysfunction mice;(ii) to genetically define the importance of the PGC11/2 and QK targets as critical mediators of the telomere checkpoint response with respect to mitochondria biology, degenerative aging, and the genesis and progression of cancer and cancer genomic changes. Second area speaks to translation of the concept of anti-telomerase therapy. Our previous work has suggested that anti-telomerase therapy should preferentially avoid patients with p53-deficient tumors. In this renewal, we will validate the principal of telomerase extinction as an anti-cancer therapy and define potential resistance mechanisms on the genomic and metabolic levels to anti-telomerase therapy. The identification of these mechanisms should lead to new drugs that may synergize with anti-telomerase therapy.
Telomere dysfunction is one of the hallmark of aging, degenerative diseases and cancer. We will validate the principal of telomerase extinction as an anti-cancer therapy and define potential resistance mechanisms which should lead to new drugs that may synergize with anti-telomerase therapy.
|Mourkioti, Foteini; Kustan, Jackie; Kraft, Peggy et al. (2013) Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy. Nat Cell Biol 15:895-904|
|Zhang, Yuqing; Shin, Sandra J; Liu, Debra et al. (2013) ZNF365 promotes stability of fragile sites and telomeres. Cancer Discov 3:798-811|
|Moslehi, Javid; DePinho, Ronald A; Sahin, Ergun (2012) Telomeres and mitochondria in the aging heart. Circ Res 110:1226-37|
|Ding, Zhihu; Wu, Chang-Jiun; Jaskelioff, Mariela et al. (2012) Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148:896-907|
|Hu, Jian; Hwang, Soyoon Sarah; Liesa, Marc et al. (2012) Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148:651-63|
|Jaskelioff, Mariela; Muller, Florian L; Paik, Ji-Hye et al. (2011) Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 469:102-6|
|Sahin, Ergun; Depinho, Ronald A (2010) Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 464:520-8|
|Artandi, Steven E; DePinho, Ronald A (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9-18|
|Polter, Abigail; Yang, Sufen; Zmijewska, Anna A et al. (2009) Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 65:150-9|
|Kimmelman, Alec C; Hezel, Aram F; Aguirre, Andrew J et al. (2008) Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A 105:19372-7|
Showing the most recent 10 out of 22 publications